In contrast, Oler and Cerutti reported that the BRAF (V600E) mutation was associated with tumour size, ETE, lymph node metastasis, high risk of recurrence and mortality in PTC patients (14). Here, BRAF is linked to metastatic malignant neoplasm in the lymph nodes.